A neuroprotective phase precedes striatal degeneration upon nucleolar stress

Cell Death and Differentiation

Volumn 20, Issue 11, 2013, Pages 1455-1464

  Kreiner, G ^a,b   Bierhoff, H ^a   Armentano, M ^c   Rodriguez Parkitna, J ^a,b   Sowodniok, K ^a   Naranjo, J R ^d   Bonfanti, L ^c   Liss, B ^e   Schutz G ^a   Grummt, I ^a   Parlato, R ^a,e,f  

^a GERMAN CANCER RESEARCH CENTER   (Germany)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c UNIVERSITY OF TURIN   (Italy)

^d CSIC   (Spain)

^e UNIVERSITY OF ULM   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Huntington's disease; neuroprotection; nucleolus; p53; PTEN

Indexed keywords

DNA DIRECTED RNA POLYMERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION INITIATION FACTOR IA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CELL FUNCTION; CELL STRESS; CELL SURVIVAL; CONTROLLED STUDY; MOUSE; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; NUCLEOLUS; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; UPREGULATION;

MAMMALIA; MUS;

ANIMALS; CELL NUCLEOLUS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; GENE KNOCKOUT TECHNIQUES; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84885400581     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.66     Document Type: Article

References (60)

1. Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci 2006; 7: 278-294.
2. Johnson FB, Marciniak RA, Guarente L. Telomeres, the nucleolus and aging. Curr Opin Cell Biol 1998; 10: 332-338.
3. Hetman M, Pietrzak M. Emerging roles of the neuronal nucleolus. Trends Neurosci 2012; 35: 305-314.
4. Pietrzak M, Rempala G, Nelson PT, Zheng JJ, Hetman M. Epigenetic silencing of nucleolar rRNA genes in Alzheimer's disease. PLoS One 2011; 6: e22585.
5. Rieker C, Engblom D, Kreiner G, Domanskyi A, Schober A, Stotz S et al. Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism through repression of mammalian target of rapamycin signaling. J Neurosci 2011; 31: 453-460.
6. Vilotti S, Codrich M, Dal Ferro M, Pinto M, Ferrer I, Collavin L et al. Parkinson's disease DJ-1 L166P alters rRNA biogenesis by exclusion of TTRAP from the nucleolus and sequestration into cytoplasmic aggregates via TRAF6. PLoS One 2012; 7: e35051.
7. Tsoi H, Lau TC, Tsang SY, Lau KF, Chan HY. CAG expansion induces nucleolar stress in polyglutamine diseases. Proc Natl Acad Sci USA 2012; 109: 13428-13433.
8. Lanni C, Racchi M, Memo M, Govoni S, Uberti D. p53 at the crossroads between cancer and neurodegeneration. Free Radic Biol Med 2012; 52: 1727-1733.
9. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
10. Mayer C, Grummt I. Cellular stress and nucleolar function. Cell Cycle 2005; 4: 1036-1038.
11. Yuan X, Zhou Y, Casanova E, Chai M, Kiss E, Grone HJ et al. Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis. Mol Cell 2005; 19: 77-87.
12. Boulon S, Westman BJ, Hutten S, Boisvert FM, Lamond AI. The nucleolus under stress. Mol Cell 2010; 40: 216-227.
13. Deisenroth C, Zhang Y. Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene 2010; 29: 4253-4260.
14. Parlato R, Kreiner G, Erdmann G, Rieker C, Stotz S, Savenkova E et al. Activation of an endogenous suicide response after perturbation of rRNA synthesis leads to neurodegen-eration in mice. J Neurosci 2008; 28: 12759-12764.
15. Hilditch-Maguire P, Trettel F, Passani LA, Auerbach A, Persichetti F, MacDonald ME. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet 2000; 9: 2789-2797.
16. Latonen L. Nucleolar aggresomes as counterparts of cytoplasmic aggresomes in proteotoxic stress. Proteasome inhibitors induce nuclear ribonucleoprotein inclusions that accumulate several key factors of neurodegenerative diseases and cancer. Bioessays 2011; 33: 386-395.
17. Carnemolla A, Fossale E, Agostoni E, Michelazzi S, Calligaris R, De Maso L et al. Rrs1 is involved in endoplasmic reticulum stress response in Huntington disease. J Biol Chem 2009; 284: 18167-18173.
18. Lee J, Hwang YJ, Boo JH, Han D, Kwon OK, Todorova K et al. Dysregulation of upstream binding factor-1 acetylation at K352 is linked to impaired ribosomal DNA transcription in Huntington's disease. Cell Death Differ 2011; 18: 1726-1735.
19. Gomes C, Smith SC, Youssef MN, Zheng JJ, Hagg T, Hetman M. RNA polymerase 1-driven transcription as a mediator of BDNF-induced neurite outgrowth. J Biol Chem 2011; 286: 4357-4363.
20. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001; 293: 493-498.
21. Ferrante RJ. Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochim Biophys Acta 2009; 1792: 506-520.
22. Garden GA, Canady KS, Lurie DI, Bothwell M, Rubel EW. A biphasic change in ribosomal conformation during transneuronal degeneration is altered by inhibition of mitochondrial, but not cytoplasmic protein synthesis. J Neurosci 1994; 14: 1994-2008.
23. Dixon J, Jones NC, Sandell LL, Jayasinghe SM, Crane J, Rey JP et al. Tcof1/Treacle is required for neural crest cell formation and proliferation deficiencies that cause craniofacial abnormalities. Proc Natl Acad Sci USA 2006; 103: 13403-13408.
24. Lemberger T, Parlato R, Dassesse D, Westphal M, Casanova E, Turiault M et al. Expression of Cre recombinase in dopaminoceptive neurons. BMC Neurosci 2007; 8: 4.
25. Strand AD, Baquet ZC, Aragaki AK, Holmans P, Yang L, Cleren C et al. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci 2007; 27: 11758-11768.
26. Ju TC, Chen HM, Lin JT, Chang CP, Chang WC, Kang JJ et al. Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease. J Cell Biol 2011; 194: 209-227.
27. Rubbi CP, Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J 2003; 22: 6068-6077.
28. Kuroda T, Murayama A, Katagiri N, Ohta YM, Fujita E, Masumoto H et al. RNA content in the nucleolus alters p53 acetylation via MYBBP1A. EMBO J 2011; 30: 1054-1066.
29. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell 2008; 133: 612-626.
30. Deckel AW, Elder R, Fuhrer G. Biphasic developmental changes in Ca2 +/calmodulin-dependent proteins in R6/2 Huntington's disease mice. Neuroreport 2002; 13: 707-711.
31. Blazquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 2011; 134(Pt 1): 119-136.
32. Hebb AL, Robertson HA, Denovan-Wright EM. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 2004; 123: 967-981.
33. Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum Mol Genet 2002; 11: 1911-1926.
34. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y et al. Regulation of PTEN transcription by p53. Mol Cell 2001; 8: 317-325.
35. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012; 13: 283-296.
36. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008; 451: 1069-1075.
37. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007; 3: 542-545.
38. Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy 2011; 7: 279-296.
39. Caudle WM, Kitsou E, Li J, Bradner J, Zhang J. A role for a novel protein, nucleolin, in Parkinson's disease. Neurosci Lett 2009; 459: 11-15.
40. Baltanas FC, Casafont I, Weruaga E, Alonso JR, Berciano MT, Lafarga M. Nucleolar disruption and cajal body disassembly are nuclear hallmarks of DNA damage-induced neurodegeneration in purkinje cells. Brain Pathol 2011; 21: 374-388.
41. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 2010; 42: 454-458.
42. Diaz-Ruiz O, Zapata A, Shan L, Zhang Y, Tomac AC, Malik N et al. Selective deletion of PTEN in dopamine neurons leads to trophic effects and adaptation of striatal medium spiny projecting neurons. PLoS One 2009; 4: e7027.
43. Domanskyi A, Geissler C, Vinnikov IA, Alter H, Schober A, Vogt MA et al. Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models. FASEB J 2011; 25: 2898-2910.
44. Zou S, El-Hage N, Podhaizer EM, Knapp PE, Hauser KF. PTEN gene silencing prevents HIV-1 gp120(IIIB)-induced degeneration of striatal neurons. J Neurovirol 2011; 17: 41-49.
45. McMahon J, Huang X, Yang J, Komatsu M, Yue Z, Qian J et al. Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis. J Neurosci 2012; 32: 15704-15714.
46. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004; 36: 585-595.
47. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006; 441: 880-884.
48. Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006; 441: 885-889.
49. Drygin D, Lin A, Bliesath J, Ho CB, O'Brien SE, Proffitt C et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res 2011; 71: 1418-1430.
50. Klapstein GJ, Levine MS. Age-dependent biphasic changes in ischemic sensitivity in the striatum of Huntington's disease R6/2 transgenic mice. J Neurophysiol 2005; 93: 758-765.
51. Hansson O, Guatteo E, Mercuri NB, Bernardi G, Li XJ, Castilho RF et al. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci 2001; 14: 1492-1504.
52. Petersen A, Larsen KE, Behr GG, Romero N, Przedborski S, Brundin P et al. Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. Hum Mol Genet 2001; 10: 1243-1254.
53. Grison A, Mantovani F, Comel A, Agostoni E, Gustincich S, Persichetti F et al. Ser46 phosphorylation and prolyl-isomerase Pin1-mediated isomerization of p53 are key events in p53-dependent apoptosis induced by mutant huntingtin. Proc Natl Acad Sci USA 2011; 108: 17979-17984.
54. Piras A, Gianetto D, Conte D, Bosone A, Vercelli A. Activation of autophagy in a rat model of retinal ischemia following high intraocular pressure. PLoS One 2011; 6: e22514.
55. Li X, Khanna A, Li N, Wang E. Circulatory miR34a as an RNAbased, noninvasive biomarker for brain aging. Aging (Albany NY) 2011; 3: 985-1002.
56. Ponti G, Aimar P, Bonfanti L. Cellular composition and cytoarchitecture of the rabbit subventricular zone and its extensions in the forebrain. J Comp Neurol 2006; 498: 491-507.
57. Bilbao A, Parkitna JR, Engblom D, Perreau-Lenz S, Sanchis-Segura C, Schneider M et al. Loss of the Ca2 +/calmodulin-dependent protein kinase type IV in dopaminoceptive neurons enhances behavioral effects of cocaine. Proc Natl Acad Sci USA 2008; 105: 17549-17554.
58. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
59. Benjamini Y, Hochberg Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B Methodol 1995; 57: 289-300.
60. Koga H, Martinez-Vicente M, Arias E, Kaushik S, Sulzer D, Cuervo AM. Constitutive upregulation of chaperone-mediated autophagy in Huntington's disease. J Neurosci 2011; 31: 18492-18505.